Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Dr Haggstrom on the Role of Osimertinib in Unresectable EGFR-Mutated NSCLC

October 31st 2024

Daniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.

Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC

October 31st 2024

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Future Research Directions in ALK+ and ROS1+ NSCLC

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

October 29th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLC

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.

Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors

October 28th 2024

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

October 28th 2024

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

October 28th 2024

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The OncFive: Top Oncology Articles for the Week of 10/20

October 26th 2024

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer

October 25th 2024

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors

October 25th 2024

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.